Technical Analysis for BMY - Bristol-Myers Squibb Company

Grade Last Price % Change Price Change
grade C 59.49 2.13% 1.24
BMY closed up 2.13 percent on Friday, September 25, 2020, on approximately normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Up
Historical BMY trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
New Downtrend Bearish 1.24%
Inside Day Range Contraction 1.24%
Down 3 Days in a Row Weakness 2.98%
Down 4 Days in a Row Weakness 2.98%
Down 5 Days in a Row Weakness 2.98%
Lower Bollinger Band Touch Weakness 2.98%
Down 3 Days in a Row Weakness 0.37%
Down 4 Days in a Row Weakness 0.37%
Down 3 Days in a Row Weakness 0.15%
Older End-of-Day Gignals for BMY ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Its principal products include Plavix for protection against fatal or non-fatal heart attack or stroke; Avapro/Avalide for the treatment of hypertension and diabetic nephropathy; Eliquis to prevent and treat venous thromboembolic disorders and stroke prevention in atrial fibrillation; Abilify, an agent for adult patients with schizophrenia, bipolar mania disorder, and depressive disorder; and Reyataz and Sustiva to treat human immunodeficiency virus. The company's products also include Baraclude, an inhibitor of hepatitis B virus; Erbitux to target and block the epidermal growth factor receptor; Sprycel for treatment of chronic myeloid leukemia in adults; Yervoy to treat metastatic melanoma; Orencia to treat adult patients with moderate to severe rheumatoid arthritis; Nulojix to prevent kidney transplant rejection; Onglyza/Kombiglyze, Byetta, and Bydureon to treat type 2 diabetes; and Forxiga for the treatment of diabetes. Its products under Phase III clinical trials include Asunaprevir and Daclatasvir, which are oral small molecule to treat hepatitis C virus infection; Peginterferon lambda, a novel type 3 interferon for hepatitis C virus infection; Elotuzumab for multiple myeloma; and Nivolumab, an anticancer treatment, as well as products under the registrational process comprises Metreleptin for the treatment of lipodystrophy. The company sells its products to wholesalers, as well as directly to distributors, retailers, hospitals, clinics, government agencies, and pharmacies. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Chemistry Biopharmaceutical Diabetes Schizophrenia Multiple Myeloma Organic Chemistry Hypertension Serious Diseases Diabetic Nephropathy Treatment Of Diabetes Atrial Fibrillation Bristol Myers Squibb Metastatic Melanoma Stroke Biopharmaceutical Products Depressive Disorder Hepatitis C Virus Infection Chronic Myeloid Leukemia Kidney Transplant Lipodystrophy Treatment Of Hypertension

Is BMY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 68.34
52 Week Low 45.76
Average Volume 9,764,696
200-Day Moving Average 60.58
50-Day Moving Average 60.47
20-Day Moving Average 59.63
10-Day Moving Average 59.06
Average True Range 1.24
ADX 26.6
+DI 19.44
-DI 31.13
Chandelier Exit (Long, 3 ATRs ) 59.25
Chandelier Exit (Short, 3 ATRs ) 60.61
Upper Bollinger Band 62.10
Lower Bollinger Band 57.16
Percent B (%b) 0.47
BandWidth 8.29
MACD Line -0.60
MACD Signal Line -0.56
MACD Histogram -0.0415
Fundamentals Value
Market Cap 97.56 Billion
Num Shares 1.64 Billion
EPS 2.74
Price-to-Earnings (P/E) Ratio 21.71
Price-to-Sales 4.94
Price-to-Book 6.80
PEG Ratio 1.93
Dividend 1.56
Dividend Yield 2.62%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 62.01
Resistance 3 (R3) 61.85 60.85 61.59
Resistance 2 (R2) 60.85 60.20 60.93 61.45
Resistance 1 (R1) 60.17 59.81 60.51 60.33 61.31
Pivot Point 59.16 59.16 59.33 59.24 59.16
Support 1 (S1) 58.48 58.52 58.82 58.65 57.67
Support 2 (S2) 57.48 58.12 57.56 57.53
Support 3 (S3) 56.80 57.48 57.39
Support 4 (S4) 56.97